What is the 13F Pro Quality Score for CABA?

13F Pro ranks Cabaletta Bio, Inc. (CABA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CABA's current score at https://13fpro.ai/research/CABA (free sign-up required for the full ranking).

Where does 13F Pro source CABA data?

All Cabaletta Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cabaletta Bio, Inc. files with the SEC under CIK 1759138. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CABA in?

Cabaletta Bio, Inc. (CABA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CABA research updated on 13F Pro?

CABA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cabaletta Bio, Inc.(CABA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1759138 CABA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CABA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cabaletta Bio, Inc. (CABA), a Healthcare sector company. CABA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Cabaletta Bio, Inc. reports net income of $-43.5M, free cash flow of $-42.6M. Top institutional holders of CABA by reported 13-F value include Bain Capital Life Sciences Investors,, JENNISON ASSOCIATES, ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. CABA trades on the Nasdaq exchange and files with the SEC under CIK 1759138. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CABA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cabaletta Bio, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-43.5M

Free Cash Flow

Q1 2026

$-42.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-44.9% YoY

$-167.9MFY 2025

FY21 $-46.3MFY22 $-53.0MFY24 $-115.9MFY25 $-167.9M

Operating Income

-37.6% YoY

$-172.2MFY 2025

FY21 $-46.3MFY22 $-54.1MFY24 $-125.1MFY25 $-172.2M

EPS (Diluted)

+10.3% YoY

$-2.10FY 2025

FY21 $-1.80FY22 $-1.81FY24 $-2.34FY25 $-2.10

Total Assets

-10.8% YoY

$165.1MFY 2025

FY21 $126.3MFY22 $117.0MFY24 $185.0MFY25 $165.1M

Op. Cash Flow

-48.6% YoY

$-131.1MFY 2025

FY21 $-34.1MFY22 $-46.4MFY24 $-88.2MFY25 $-131.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-167.9M -44.9%	$-115.9M -118.7%	$-53.0M -14.4%	$-46.3M -38.8%	$-33.3M -96.8%	$-16.9M
Operating Income	$-172.2M -37.6%	$-125.1M -131.1%	$-54.1M -16.9%	$-46.3M -36.9%	$-33.8M -81.1%	$-18.7M
EPS (Diluted)	$-2.10 +10.3%	$-2.34 -29.3%	$-1.81 -0.6%	$-1.80	—	—
Total Assets	$165.1M -10.8%	$185.0M +58.2%	$117.0M -7.4%	$126.3M +10.1%	$114.7M -18.9%	$141.5M
Operating Cash Flow	$-131.1M -48.6%	$-88.2M -90.2%	$-46.4M -36.0%	$-34.1M -27.4%	$-26.8M -66.8%	$-16.0M

AI Insight: CABA Financial Trends

Cabaletta is a pre-revenue biotech burning ~$44M quarterly with equity eroded 48% since Q2 2024, leaving runway materially constrained.

• Operating losses stabilized at $43–47M/quarter in 2025–Q1 2026 after widening from $30M in Q2 2024.

• Operating cash burn averaged $30–35M/quarter in 2025–Q1 2026, up sharply from $20–21M in Q2–Q3 2024.

• Shareholder equity collapsed from $200M (Q2 2024) to $103M (Q1 2026), a 48% decline in 18 months.

⚠ Operating cash burn accelerated to $43M in Q1 2026, the highest quarterly burn on record; equity runway ~2–3 quarters at current burn.

⚠ No revenue generation evident across all eight quarters; clinical/regulatory milestone timing and financing needs remain critical unknowns.

AI Insight: CABA Ratio Trends

Cabaletta Bio's cash burn and negative returns have intensified dramatically, with ROE deteriorating from -55.3% in Q2 2024 to -168.5% in Q1 2026.

• ROE worsened from -55.3% (Q2 2024) to -168.5% (Q1 2026), a 113pp deterioration over nine quarters.

• ROA declined from -50.8% (Q2 2024) to -94.6% (Q3 2025), reflecting accelerating asset-base losses.

⚠ ROE dropped another 18.9pp from Q4 2025 to Q1 2026; trajectory suggests continued cash depletion without revenue offset.

⚠ ROIC data gaps from Q1 2025 onward limit visibility; prior readings were severely negative (-60.7% to -88.7%).

Get alerted when CABA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cabaletta Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CABA

Bain Capital Life Sciences Investors, LLC
$26.0M9,677,125 sh
JENNISON ASSOCIATES LLC
$24.1M8,970,578 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$23.8M8,829,758 sh
MILLENNIUM MANAGEMENT LLC
$15.9M5,903,281 sh
Cormorant Asset Management, LP
$14.8M5,500,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.8M4,028,991 sh
TWO SIGMA INVESTMENTS, LP
$6.7M2,497,917 sh
BlackRock, Inc.
$6.4M2,373,003 sh
MARSHALL WACE, LLP
$5.9M2,179,818 sh
RENAISSANCE TECHNOLOGIES LLC
$5.5M2,036,663 sh

Fund	Value	Shares
Bain Capital Life Sciences Investors, LLC	$26.0M	9,677,125
JENNISON ASSOCIATES LLC	$24.1M	8,970,578
ADAGE CAPITAL PARTNERS GP, L.L.C.	$23.8M	8,829,758
MILLENNIUM MANAGEMENT LLC	$15.9M	5,903,281
Cormorant Asset Management, LP	$14.8M	5,500,000
VANGUARD CAPITAL MANAGEMENT LLC	$10.8M	4,028,991
TWO SIGMA INVESTMENTS, LP	$6.7M	2,497,917
BlackRock, Inc.	$6.4M	2,373,003
MARSHALL WACE, LLP	$5.9M	2,179,818
RENAISSANCE TECHNOLOGIES LLC	$5.5M	2,036,663

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CABA on your watchlist

Track score changes the day Cabaletta Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CABA a good stock to buy?

13F Pro's AI-powered analysis of Cabaletta Bio, Inc. (CABA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CABA are available on the CABA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CABA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CABA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cabaletta Bio, Inc.'s investment landscape.